Background: Aβ42 deposition plays a pivotal role in AD pathogenesis by inducing the activation of microglial cells and neuroinflammation. This process is antagonized by microglia-mediated clearance of Aβ plaques. Activation of the NLRP3 inflammasome is involved in neuroinflammation and in the impairments of Aβ-plaque clearance. On the other hand, stavudine (D4T) downregulates the NLRP3 inflammasome and stimulates autophagy-mediated Aβ-clearing in a THP-1-derived macrophages. Methods: We explored the effect of D4T on Aβ autophagy in PBMC from AD patients that were primed with LPS and stimulated with Aβ oligomers in the absence/presence of D4T. We analyzed the NLRP3 activity by measuring NLRP3-ASC complex formation by AMNIS FlowSight and pro-inflammatory cytokine (IL-1β, IL-18 and Caspase-1) production by ELISA. The phosphorylation status of p38, ERK, AKT, p70, and the protein expression of CREB, LAMP2A, beclin-1, Caspase-3 and Bcl2 were analyzed by Western blot. Results: Data showed that D4T: (1) downregulates NLRP3 inflammasome activation and the production of down-stream pro-inflammatory cytokines in PBMC; (2) stimulates the phosphorylation of AKT, ERK and p70 as well as LAMP2A, beclin-1 and Bcl2 expression and reduces Caspase-3 expression, suggesting an effect of this compound on autophagy; (3) increases phospho-CREB, which is a downstream target of p-ERK and p-AKT, inducing anti-inflammatory cytokine production and resulting in a possible decrease of Aβ-mediated cytotoxicity; and (4) reduces the phosphorylation of p38, a protein involved in the production of pro-inflammatory cytokines and tau hyperphosphorylation. Conclusions: D4T reduces the activation of the NLRP3 inflammasome, and it might stimulate autophagy as well as the molecular mechanism that modulates Aβ cytotoxicity, and D4T might reduce inflammation in the cells of AD patients. It could be very interesting to check the possible beneficial effects of D4T in the clinical scenario.
Activation of the NLRP3 inflammasome in response to either exogenous (PAMPs) or endogenous (DAMPs) stimuli results in the production of IL-18, caspase-1 and IL-1β. These cytokines have a beneficial role in promoting inflammation, but an excessive activation of the inflammasome and the consequent constitutive inflammatory status plays a role in human pathologies, including Alzheimer’s disease (AD). Autophagic removal of NLRP3 inflammasome activators can reduce inflammasome activation and inflammation. Likewise, inflammasome signaling pathways regulate autophagy, allowing the development of inflammatory responses but preventing excessive and detrimental inflammation. Nanotechnology led to the development of liposome engineered nanovectors (NVs) that can load and carry drugs. We verified in an in vitro model of AD-associated inflammation the ability of Glibenclamide-loaded NVs (GNVs) to modulate the balance between inflammasome activation and autophagy. Human THP1dM cells were LPS-primed and oligomeric Aß-stimulated in the presence/absence of GNVs. IL-1β, IL-18 and activated caspase-1 production was evaluated by the Automated Immunoassay System (ELLA); ASC speck formation (a marker of NLRP3 activation) was analyzed by FlowSight Imaging flow-cytometer (AMNIS); the expression of autophagy targets was investigated by RT-PCR and Western blot (WB); and the modulation of autophagy-related up-stream signaling pathways and Tau phosphorylation were WB-quantified. Results showed that GNVs reduce activation of the NLRP3 inflammasome and prevent the Aß-induced phosphorylation of ERK, AKT, and p70S6 kinases, potentiating autophagic flux and counteracting Tau phosphorylation. These preliminary results support the investigation of GNVs as a possible novel strategy in disease and rehabilitation to reduce inflammasome-associated inflammation.
17 September 2026 in Journal of Cerebral Blood Flow & Metabolism
Background: Remote ischemic conditioning (RIC) is a promising neuroprotective strategy for ischemic stroke, but reliable pharmacodynamic biomarkers confirming its biological activity are lacking. Methods: In this translational sub-study of the multicenter randomized phase II TRICS-9 trial, we profiled five circulating microRNAs (miR-181b, miR-150, miR-143, miR-223, and let-7a) in 42 acute stroke patients assigned to RIC or standard medical therapy at 24 h and 72 h post-randomization. Results: At 24 h, miR-143, miR-150, and let-7a were significantly lower in RIC patients, with miR-143 and miR-150 showing strong pharmacodynamic biomarker performance in receiver operating characteristic analysis. At 72 h, miR-181b was significantly elevated in RIC patients, while let-7a and miR-223 remained suppressed. Longitudinal paired analysis revealed significant within-patient temporal increases in miR-181b, miR-150, and miR-143 from 24 to 72 h in RIC patients consistent with a biphasic molecular response to conditioning. Conclusions: These findings identify miR-143, miR-150, let-7a, and miR-181b as candidate pharmacodynamic biomarkers of RIC biological activity. Importantly, none of the candidate miRNAs demonstrated significant correlation with stroke severity, discharge NIHSS, or 90-day functional outcome, consistent with their role as pharmacodynamic rather than prognostic markers. These results provide mechanistic support for translational convergence between preclinical and clinical RIC neuroprotection research and highlight the need for external validation in larger outcome-linked cohorts.
1 October 2021 in Journal of Investigative Dermatology
TH9 cells, also known as pathogenic TH2 cells, are a subset of proinflammatory effector TH cells characterized by high levels of IL-9 expression. They share many properties with conventional TH2 cells but are distinguished by their expression of the transcription factor PPAR-γ, on which they depend for full effector function. PPAR-γ is best known for its role in controlling lipid and glucose metabolism but is increasingly implicated in type 2 inflammation. However, the role of PPAR-γ in TH9 cells remains unclear. Transcriptional profiling of human TH9 cells in presence or absence of the PPAR-γ inhibitor, GW9662, showed strong upregulation of genes involved in cystine transport and redox control of lipid peroxidation. One of the top upregulated genes was SLC7A11, which encodes a cystine/glutamate transporter. Interestingly, we found that the chemical inhibition of SLC7A11 by erastin and cystine starvation in cystine free medium leads to an increase in lipid ROS levels and cell death in TH9 cells but not in conventional TH2 cells. Moreover, PPAR-γ inhibition promotes a further increase in lipid ROS and cell death upon erastin treatment only in TH9 cells, and this effect was not associated with augmented cellular ROS or mitochondrial ROS. Importantly, the anti-oxidant N-acetylcysteine completely rescued the effect of erastin, alone or in combination with GW9662. Erastin and/or GW9662 were also able to selectively deplete the CCR8+CRTh2+ effector memory T cells isolated from allergic contact dermatitis skin biopsies, which share phenotypic and functional features with TH9 cells. These preliminary data suggest that PPAR-y plays a role in protecting pathogenic TH2 cells from unchecked lipid ROS and consecutive cell death. Our findings open up new therapeutic avenues to selectively target pathogenic TH2 cells in the treatment of allergic diseases by leveraging their particular dependency on cystine to prevent cell death from unchecked lipid ROS.